In 2009, Fong and colleagues [163] published their results from a phase I trial with the PARP inhibitor olaparib involving 60 tumor patients enriched in BRCA mutation carriers, including 16 hereditary ovarian carcinoma patients. This evidence concerns the gene PARP1 and neoplasm.